β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development
Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel combinations of β-lactams/β-lactamase inhibitors...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/14/2/168 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850229886673747968 |
|---|---|
| author | Angeliki Katsarou Panagiotis Stathopoulos Iva D. Tzvetanova Christina-Maria Asimotou Matthew E. Falagas |
| author_facet | Angeliki Katsarou Panagiotis Stathopoulos Iva D. Tzvetanova Christina-Maria Asimotou Matthew E. Falagas |
| author_sort | Angeliki Katsarou |
| collection | DOAJ |
| description | Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel combinations of β-lactams/β-lactamase inhibitors against multidrug-resistant (MDR) Gram-negative pathogens, which remain the major concern in clinical practice. The incorporation of ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/cilastatin/relebactam has provided new therapeutic options in the treatment of patients with infections due to MDR pathogens. Cefiderocol along with cefepime/enmetazobactam, avibactam/aztreonam, and sulbactam/durlobactam have been recently added to these agents as therapeutic choices, particularly for metallo-β-lactamase producing Gram-negative bacteria. Currently, many combinations are being studied for their in vitro activity against both serine- and metallo-β-lactamases. However, only a few have advanced through phase 1, 2, and 3 clinical trials. Among them, in this article, we focus on the most promising combinations of cefepime/zidebactam, cefepime/taniborbactam, and imipenem/cilastatin/funobactam, which are currently under investigation in phase 3 trials. |
| format | Article |
| id | doaj-art-6e0d1feda55040f396e59632f0990656 |
| institution | OA Journals |
| issn | 2076-0817 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj-art-6e0d1feda55040f396e59632f09906562025-08-20T02:04:02ZengMDPI AGPathogens2076-08172025-02-0114216810.3390/pathogens14020168β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under DevelopmentAngeliki Katsarou0Panagiotis Stathopoulos1Iva D. Tzvetanova2Christina-Maria Asimotou3Matthew E. Falagas4Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Athens, GreeceAlfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Athens, GreeceSchool of Medicine, European University Cyprus, 6 Diogenous Street, 2404 Nicosia, CyprusAlfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Athens, GreeceAlfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Athens, GreeceAntimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel combinations of β-lactams/β-lactamase inhibitors against multidrug-resistant (MDR) Gram-negative pathogens, which remain the major concern in clinical practice. The incorporation of ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/cilastatin/relebactam has provided new therapeutic options in the treatment of patients with infections due to MDR pathogens. Cefiderocol along with cefepime/enmetazobactam, avibactam/aztreonam, and sulbactam/durlobactam have been recently added to these agents as therapeutic choices, particularly for metallo-β-lactamase producing Gram-negative bacteria. Currently, many combinations are being studied for their in vitro activity against both serine- and metallo-β-lactamases. However, only a few have advanced through phase 1, 2, and 3 clinical trials. Among them, in this article, we focus on the most promising combinations of cefepime/zidebactam, cefepime/taniborbactam, and imipenem/cilastatin/funobactam, which are currently under investigation in phase 3 trials.https://www.mdpi.com/2076-0817/14/2/168antimicrobial resistancemetallo-β-lactamasesβ-lactams/β-lactamase inhibitorscefepime/zidebactamcefepime/taniborbactamimipenem/cilastatin/funobactam |
| spellingShingle | Angeliki Katsarou Panagiotis Stathopoulos Iva D. Tzvetanova Christina-Maria Asimotou Matthew E. Falagas β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development Pathogens antimicrobial resistance metallo-β-lactamases β-lactams/β-lactamase inhibitors cefepime/zidebactam cefepime/taniborbactam imipenem/cilastatin/funobactam |
| title | β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development |
| title_full | β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development |
| title_fullStr | β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development |
| title_full_unstemmed | β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development |
| title_short | β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development |
| title_sort | β lactam β lactamase inhibitor combination antibiotics under development |
| topic | antimicrobial resistance metallo-β-lactamases β-lactams/β-lactamase inhibitors cefepime/zidebactam cefepime/taniborbactam imipenem/cilastatin/funobactam |
| url | https://www.mdpi.com/2076-0817/14/2/168 |
| work_keys_str_mv | AT angelikikatsarou blactamblactamaseinhibitorcombinationantibioticsunderdevelopment AT panagiotisstathopoulos blactamblactamaseinhibitorcombinationantibioticsunderdevelopment AT ivadtzvetanova blactamblactamaseinhibitorcombinationantibioticsunderdevelopment AT christinamariaasimotou blactamblactamaseinhibitorcombinationantibioticsunderdevelopment AT matthewefalagas blactamblactamaseinhibitorcombinationantibioticsunderdevelopment |